Isoniazid (INH) is an antibiotic indicated in the first-line treatment of active Mycobacterium tuberculosis infection. The US Food and Drug Administration (FDA) approved INH for the following indications: Active tuberculosis (TB) infection can present as fever, chills, night sweats, cough, hemoptysis, and weight loss.